Washington, D.C.—The Natural Products Association (NPA) announced in a press release that former FDA official Sibyl Swift, Ph.D., will be the new SVP for Scientific and Regulatory Affairs for the association.
Dr. Swift most recently held the position of Associate Director for Research and Strategy at the Office of Dietary Supplement Programs, wherein she managed the office’s research portfolio and was responsible for aligning its science, research, compliance, enforcement, and policy initiatives. She also co-chaired the Steering Team for the Botanical Safety Consortium.
Related: NPA Asks for Defined Standards for Cosmetics
FDA: Botanical Safety Consortium Formally Convened
Dietary Supplements Regulatory Summit: Industry/FDA Unite; Discuss Future of DSHEA
In her role at NPA, Dr. Swift will be responsible for the development and implementation of the association’s current educational, regulatory, and compliance programs and efforts, such as SSCI, the NPA Natural Standard, and others. Her work will also include a focus on assisting members with NDI notification policy and claim reviews and substantiation.
Dr. Swift said in the release: “I’m excited to be joining NPA at this promising phase for this important and growing industry. As Americans and their elected officials look for ‘health-first’ strategies that promote wellness over treatment and reduce costs, I’m confident that natural products will play a larger role. I can’t wait to get to work.”
Daniel Fabricant, Ph.D., President and CEO of NPA, added: “We are very excited that Dr. Swift is a part of NPA as we enter this important phase of industry regulation and expansion, especially as it relates to new and promising products like CBD. Dr. Swift is an exceptional example of NPA’s leadership and focus on effectively engaging in legislative and regulatory environments to support the industry and ensure the best, safest, and most innovative natural products are accessible to people in America and around the world. No other organization in the space has this depth and breadth of understanding of how the modern-day FDA functions.”